newsfilter
← Latest News
PR Newswire·

Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences

PALO ALTO, Calif., Sept. 1, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, to